Delivery Order SPE2DB22D3401-SPE2DB25FT5WG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,073.80 to AmerisourceBergen Drug Corp for AJOVY 225 mg/1.5 mL auto-injector units on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order, which is not subject to a set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of AJOVY 225 mg/1.5 mL auto-injector medication, valued at $1,300.58. This is a firm fixed-price delivery order with no set-aside designation, executed competitively under the company's larger indefinite delivery contract (IDC) vehicle with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $4,376.49 delivery order to AmerisourceBergen Drug Corp for AJOVY (fremanezumab) 225 mg/1.5 mL auto-injector auto-injectors, with delivery to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 14, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 11, 2025, for the supply of AJOVY 225 mg/1.5 ml auto-injector units. The contract carries a ceiling value of $7,564.38 and is structured as a firm fixed-price delivery order with an ultimate completion date of August 12, 2025. This award represents a non-set-aside competitive procurement and is performed at the vendor's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ajovy 225 mg/1.5 mL auto-injectors, with a ceiling value of $1,092.00 and a completion date of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and designates AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,554.55 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of AJOVY 225 mg/1.5 mL auto-injector units. The contract is classified as a firm fixed price delivery order with an ultimate completion date of August 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award utilized no set-aside provisions, reflecting the competitive nature of the procurement. AmerisourceBergen Drug Corp, a...
- The Defense Logistics Agency awarded a $116,110 firm fixed price delivery order to Amerisourcebergen Drug Corporation for AJOVY 225 MG/1.5 ML autoinjectors. The single award was issued under an undisclosed government-wide acquisition contract vehicle or blanket purchase agreement held by Amerisourcebergen. Performance will occur at the prime contractor's facility in Conshohocken, Pennsylvania over a one day period from July 27 to July 28, 2023. No subcontractors or set aside designations were...
- The Defense Logistics Agency awarded a $348,330 firm fixed price delivery order to Amerisourcebergen Drug Corporation for AJOVY 225 MG/1.5 ML autoinjectors. The single-award contract supports DLA's medical supply needs and calls for Amerisourcebergen to deliver 1.5mL autoinjectors of AJOVY, a medication used to prevent migraines, to a location in Conshohocken, Pennsylvania by July 14, 2023. No subcontractors or set-aside designations were identified. The delivery order was issued against an...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,847.18 to AmerisourceBergen Drug Corp's Corporate Office Division for the supply of AJOVY 225 MG/1.5 ML AUTOINJECT 1.5ML, a pharmaceutical product. This order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which provides a comprehensive range of medical commodities to support military treatment programs and facilities...
- The Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order contract to Amerisourcebergen Drug Corp for the supply of AJOVY 225 MG/1.5 ML AUTOINJECT 1.5ML pharmaceutical products. The $1,055.52 firm fixed-price contract has a completion date of September 20, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for a comprehensive range of...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5WGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of AJOVY (eptinezumab) 225 mg/1.5 mL auto-injector units valued at $1,187.64. This firm fixed-price delivery order, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the Place of Performance located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and primary distribution hub for federal medical procurement. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical devices to support military and veteran healthcare systems. AJOVY, a CGRP monoclonal antibody indicated for migraine prevention, represents the type of specialty pharmaceutical products the company routinely provides to Defense Health Agency and other federal healthcare customers through this strategic contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/27/25 |